Showing 2721-2730 of 3858 results for "".
- Novartis to Present CSU, HS Data for Remibrutinib, Secukinumabhttps://practicaldermatology.com/news/Novartis-Present-CSU-HS-Data-Remibrutinib-Secukinumab/2471383/Novartis announced it will present data from 17 abstracts, including investigator-initiated trials, across its immunology portfolio at the 2025 American Academy of Dermatology (AAD) Annual Meeting and the 2025 American Academy of Allergy Asthma and Immunology (AAAAI) and World Allergy Organizatio
- Dr. Swanson: Dupilumab/Vaccines Question Has Been Answeredhttps://practicaldermatology.com/news/Dr-Swanson-Dupilumab-Vaccines-Question-Has-Been-Answered/2471166/The biggest remaining question about dupilumab has been answered by the allergy and immunology community, Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, said at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii. “The only realy question
- Nemolizumab Approved by European Commission for Moderate-to-severe Prurigo Nodularishttps://practicaldermatology.com/news/nemolizumab-approved-european-commission-for-moderate-to-severe-prurigo-nodularis/2471164/Nemolizumab has been approved by the European Commission for the treatment of moderate-to-severe prurigo nodularis, according to an announcement from Galderma. The approval of the monoclonal antibody (marketed as Nemluvio) fol
- VYNE Therapeutics Completes Enrollment for Phase 2b Trial of VYN201 in Nonsegmental Vitiligohttps://practicaldermatology.com/news/vyne-therapeutics-completes-enrollment-phase-2b-trial-vyn201-nonsegmental-vitiligo/2470854/VYNE Therapeutics Inc. has finalized enrollment for its Phase 2b trial of VYN201, a once-daily topical gel for nonsegmental vitiligo, with initial data from the 24-week double-blind portion anticipated in mid-2025, according to a news release from the manufacturer. The randomized, double-b
- OLYMPIA 1: Nemolizumab Shows Improvements in Prurigo Nodularis Symptomshttps://practicaldermatology.com/news/olympia-1-nemolizumab-shows-improvements-prurigo-nodularis-symptoms/2468705/Results from a multicenter phase 3 clinical trial indicated that nemolizumab monotherapy significantly reduces pruritus and nodular lesions in adults with moderate to severe prurigo nodularis (PN). Researchers for the OLYMPIA 1 trial evaluated the efficacy and safety of nemolizumab in 286
- T-VASI and F-VASI Shown Reliable in Nonsegmental Vitiligo Assessmenthttps://practicaldermatology.com/news/t-vasi-and-f-vasi-shown-reliable-nonsegmental-vitiligo-assessment/2468550/New research confirmed that the Total Vitiligo Area Scoring Index (T-VASI) and the Facial VASI (F-VASI) are reliable and valid tools for measuring meaningful improvement in patients with nonsegmental vitiligo. The study, published in JAMA Dermatology, included 164 adult participa
- World Hair Transplant Repair Day Set for November 11https://practicaldermatology.com/news/world-hair-transplant-repair-day-set-november-11/2468428/The International Society of Hair Restoration Surgery (ISHRS) will host its annual “World Hair Transplant Repair Day” on November 11, part of the ISHRS’s Fight the FIGHT (an acronym for Fight the Fraudulent, Illicit, and Global Hair Transplants) global consumer awareness campaign designed to educ
- Report: Nonsurgical Aesthetics Revenues Up 9%https://practicaldermatology.com/news/report-nonsurgical-aesthetics-revenues-9/2468303/Data and analytics solutions provider Guidepoint Qsight and investment banking and management consulting firm Skytale Group released a new report on the state of the aesthetics industry, highlighting the continued expansion of the US market. Combined nonsurgical revenues increased by 9% in
- IGSRT Shows High Recurrence-Free Rates in Non-Melanoma Skin Cancerhttps://practicaldermatology.com/news/igsrt-shows-high-recurrence-free-rates-non-melanoma-skin-cancer/2468185/Nonmelanoma skin cancer (NMSC) treated with Image-Guided Superficial Radiation Therapy (IGSRT) showed consistently high freedom from recurrence rates, regardless of patient age or sex, according to a new analysis. The large retrospective cohort study, published in Geriatrics and c
- FDA Approves Nemluvio for Prurigo Nodularis Treatmenthttps://practicaldermatology.com/news/fda-approves-nemluvio-prurigo-nodularis-treatment/2467770/The U.S. Food and Drug Administration (FDA) has approved Galderma's Nemluvio® (nemolizumab) for the treatment of adults with prurigo nodularis, according to a news release. Nemolizumab, a monoclonal antibody IL-31 inhibitor, targets a neuroimmune cytokine implicated in prurigo nodularis p